Use of a nitric oxide (ISMN) for the PREVENTION and MANAGEMENT of pre-eclampsia (pilot study)
| ISRCTN | ISRCTN45790835 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN45790835 |
| Secondary identifying numbers | FMI-63194 |
- Submission date
- 29/11/2006
- Registration date
- 21/12/2007
- Last edited
- 03/03/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Graeme Smith
Scientific
Scientific
Clinical Research Centre
Queen's University
Kingston General Hospital
76 Stuart Street, Angada 4, Room 5-415
Kingston
K7L 2V7
Canada
| Phone | +1 613 549 6666 ext. 3936 |
|---|---|
| gns@post.queensu.ca |
Study information
| Study design | Randomised, multicentre, blinded, placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A pilot study to evaluate glyceryl trinitrate (GTN) as a novel therapeutic for the prevention and treatment of pre-eclampsia |
| Study objectives | CIHR Grant Submission Title: Pre-eclampsia: Fetal and Maternal Outcomes and Innovative Therapies To determine if exogenous glyceryl trinitrate (GTN), compared to placebo, will be effective at preventing the development and/or progression of clinical pre-eclampsia. |
| Ethics approval(s) | Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board, Kingston, Ontario (Canada) approved on the 20th September 2002 (ref: ANAT-017-02) |
| Health condition(s) or problem(s) studied | Pre-eclampsia |
| Intervention | The study is a randomised blinded drug/placebo trial. The randomisation scheme was prepared by an independent statistician prior to initiation of the pilot study, and prepared in blocks for if and when Ottawa Hospital comes on board. The study investigators, associated staff, outcome assessor, data analyst and the study participants will all be blinded to the treatment allocation. ISMN and placebo capsules will be prepared to have identical shape, size, color, smell and feel. No form of identification labeling will be visible on either intervention. When a suitable participant is identified, the research nurse coordinator will explain the details and potential risks and benefits of the study. If consent is granted, the research nurse coordinator will determine the treatment assignment for that subject by calling the research pharmacist who will provide the next code indicating the treatment for a given patient. Patients will then be provided with an appropriately labeled package of pills prepared by the hospital pharmacy. Prevention Arm: Experimental intervention: Daily dose of low dose Isosorbide-5-mononitrate (ISMN) (30 mg) beginning after 20 weeks gestation till delivery. Control intervention: Matching placebo containing lactose. Patients randomly assigned to either receive low dose ISMN (30 mg) as stated above or placebo. Management Arm: Experimental intervention: Daily dose of low dose Isosorbide-5-mononitrate (ISMN) (30 mg) following diagnosis of pre-eclampsia after 24 weeks gestation till delivery. Control intervention: Matching placebo containing lactose. Patients randomly assigned to either receive low dose ISMN (30 mg) as stated above or placebo. In both arms of the study, patients will receive standard clinical care. Total duration of treatment in each arm is flexible and based on each individual participant. There is no follow-up after delivery. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Glyceryl trinitrate |
| Primary outcome measure | Prevention arm: incidence of pre-eclampsia in the ISMN/placebo groups, measured at delivery Treatment arm: randomisation-to-delivery interval between ISMN/placebo groups, measured at delivery |
| Secondary outcome measures | 1. Serial change in biochemical markers in treatment/no treatment groups in each of the studies, measured at routine obstetrical visits until delivery (generally every 2 weeks) 2. Incidence of any side effects (major or minor), measured at routine obstetrical visits until delivery (generally every 2 weeks) 3. Neonatal outcomes (composite of neonatal morbidity), measured at delivery |
| Overall study start date | 01/01/2007 |
| Completion date | 31/12/2009 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Female |
| Target number of participants | 80 women in total: prevention arm (40), treatment arm (40) |
| Key inclusion criteria | Women of childbearing years (approximately 18 - 42 years). Prevention arm: All women with a past obstetrical history of one or more cases of severe early onset pre-eclampsia or later onset severe pre-eclampsia associated with haemolysis, elevated liver enzymes, low blood levels of platelets (HELLP) syndrome. Treatment arm: All women that have been diagnosed with pre-eclampsia that are being followed clinically and that provide informed consent. For a diagnosis of pre-eclampsia a patient must meet all three criteria: 1. Systolic blood pressure greater than 140 mmHg or an increase of 30 mmHg from the participants baseline (with that increase present at two measurements taken 6 hours apart) 2. Diastolic blood pressure greater than 90 mmHg or an increase of 15 mmHg from the participants baseline (with that increase present at two measurements taken 6 hours apart) 3. Proteinuria greater than 0.3 g in 24 hour urine or 2+ on dipstick |
| Key exclusion criteria | Potential women excluded are those: 1. That have a contraindication to use of isosorbide mononitrate (ISMN) 2. That have either a maternal or foetal indication for delivery 3. That have a diagnosis of severe pre-eclampsia (diastolic blood pressure greater than 100 mmHg; proteinuria greater than 1 g/d), eclampsia, or HELLP syndrome at time of recruitment |
| Date of first enrolment | 01/01/2007 |
| Date of final enrolment | 31/12/2009 |
Locations
Countries of recruitment
- Canada
Study participating centre
Clinical Research Centre
Kingston
K7L 2V7
Canada
K7L 2V7
Canada
Sponsor information
Queen's University (Canada)
University/education
University/education
99 University Avenue
Kingston
K7L 3N6
Canada
| gns@post.queensu.ca | |
| Website | http://www.queensu.ca/homepage/ |
"ROR" |
https://ror.org/02y72wh86 |
Funders
Funder type
Research organisation
Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: FMI-63194)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
